



Please type a sign (+) inside this box ! +

PTO/SB/05 (08-00)

Approved for use through 10/31/2002. OMB 0651-0032  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>UTILITY PATENT APPLICATION TRANSMITTAL</b> <small>(Only for new nonprovisional applications under 37 CFR ' 1.53(b))</small>		Attorney Docket No. <b>PZ022P1C2</b>	
		First Inventor	<b>LaFleur et al.</b>
		Title	<b>36 Human Secreted Proteins</b>
		Express Mail Label No.	
<b>APPLICATION ELEMENTS</b> <small>See MPEP chapter 600 concerning utility patent application contents.</small>		<b>ADDRESS TO:</b> Assistant Commissioner for Patents Box Patent Application Washington, DC 20231	
1. <input checked="" type="checkbox"/> Fee Transmittal Form (e.g., PTO/SB/17) <small>(Submit an original, and a duplicate for fee processing)</small>		7. <input type="checkbox"/> CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix)	
2. <input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27.		8. Nucleotide and/or Amino Acid Sequence Submission <small>(if applicable, all necessary)</small>	
3. <input checked="" type="checkbox"/> Specification [Total Pages <b>191</b> ] <small>(preferred arrangement set forth below)</small> <ul style="list-style-type: none"><li>- Descriptive title of the Invention</li><li>- Cross Reference to Related Applications</li><li>- Statement Regarding Fed sponsored R &amp; D</li><li>- Reference to sequence listing, a table, or a computer program listing appendix</li><li>- Background of the Invention</li><li>- Brief Summary of the Invention</li><li>- Brief Description of the Drawings (if filed)</li><li>- Detailed Description</li><li>- Claim(s)</li><li>- Abstract of the Disclosure</li></ul>		a. <input type="checkbox"/> Computer Readable Form (CRF)	
4. <input type="checkbox"/> Drawing(s) (35 U.S.C. 113) [Total Sheets <b>  </b> ]		b. Specification Sequence Listing on: <ul style="list-style-type: none"><li>i. <input type="checkbox"/> CD-ROM or CD-R (2 copies); or</li><li>ii. <input checked="" type="checkbox"/> paper</li></ul>	
5. <input checked="" type="checkbox"/> Oath or Declaration [Total Pages <b>6</b> ] <ul style="list-style-type: none"><li>a. <input type="checkbox"/> Newly executed (original or copy)</li><li>b. <input checked="" type="checkbox"/> Copy from a prior application (37 CFR 1.63(d)) <small>(for continuation/divisional with Box 17 completed)</small></li><li>i. <input type="checkbox"/> <b>DELETION OF INVENTOR(S)</b> <small>Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR ' ' 1.63(d)(2) and 1.33(b).</small></li></ul>		c. Request under 37 CFR 1.821(e)	
6. <input type="checkbox"/> Application Data Sheet. See 37 CFR 1.76.		<b>ACCOMPANYING APPLICATION PARTS</b>	
17. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76: <div style="display: flex; justify-content: space-between;"><div><input checked="" type="checkbox"/> Continuation    <input type="checkbox"/> Divisional    <input type="checkbox"/> Continuation-in-Part (CIP)</div><div>of prior application No: 09/739,907</div></div> <p><small>Prior application information: Examiner Whisenant, E. Group/Art Unit: 1655</small></p> <p><small>For CONTINUATION OR DIVISIONAL APPS only The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.</small></p>		9. <input type="checkbox"/> Assignment Papers (cover sheet and document(s))	
		10. <input type="checkbox"/> 37 CFR 3.73(b) Statement <input type="checkbox"/> Power of Attorney	
		11. <input type="checkbox"/> English Translation Document (if applicable)	
		12. <input type="checkbox"/> Information Disclosure Statement/ Form PTO/SB/08 <input type="checkbox"/> Copies of Citations	
		13. <input checked="" type="checkbox"/> Preliminary Amendment w/ Version with Markings to Show Changes Made	
		14. <input checked="" type="checkbox"/> Return Receipt Postcard (MPEP 503) <small>(should be specifically itemized)</small>	
		15. <input type="checkbox"/> Certified copy of Priority Document(s) <small>(if foreign priority is claimed)</small>	
		16. <input type="checkbox"/> Other:	
<b>18. CORRESPONDENCE ADDRESS</b>			
<input checked="" type="checkbox"/> Customer Number or Bar Code Label <b>22195</b> or <input type="checkbox"/> Correspondence address below			
NAME			
ADDRESS			
CITY		STATE	ZIP CODE
COUNTRY		TELEPHONE	FAX
NAME (Print/Type) <b>Janet M. Martineau</b>		Registration No. (Attorney/Agent) <b>46,903</b>	
SIGNATURE		Date <b>August 27, 2001</b>	

Statement: this form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete could be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Box Patent Application, Washington, DC 20231.

## FEE TRANSMITTAL for FY 2001

*Patent fees are subject to annual revision.*

**Complete if Known**

	Application Number	Unassigned
	Filing Date	August 27, 2001
	First Named Inventor	LaFleur et al.
	Examiner Name	
	Group Art Unit	
Total amount of payment	(\$) <b>862.00</b>	Attorney Docket Number
		<b>PZ022P1C2</b>

### METHOD OF PAYMENT (CHECK ONE)

1. ☒ The Commissioner is hereby authorized to charge indicated fees and credit any overpayment to:
- Deposit Account Number **08-3425**
- Deposit Account Name **Human Genome Sciences, Inc.**
- ☒ Charge Any Additional Fee Required Under 37 CFR §§ 1.16 and 1.17
- ☐ Applicant claims small entity status
- See 37 CFR 1.27

2. ☐ Payment Enclosed:
- ☐ Check ☐ Credit Card ☐ Money Order ☒ Other\*
- \* Charge any deficiencies or credit any overpayments in the fees or fee calculations of Parts 1, 2 and 3 below to Deposit Account No. 08-3425

### FEE CALCULATION

#### 1. BASIC FILING FEE

Large Fee Code	Entity Fee (\$)	Small Fee Code	Entity Fee (\$)	Fee Description	Fee Paid
101	710	201	355	Utility filing fee	\$710.00
106	320	206	160	Design filing fee	
107	490	207	245	Plant filing fee	
108	710	208	355	Reissue filing fee	
114	150	214	75	Provisional filing fee	
<b>Subtotal (1)</b>					<b>\$710.00</b>

#### 2. EXTRA CLAIM FEES

	Total claims	Extra	Fee from below	Fee Paid
	24	- 20**	4	\$72.00
Indep. claims	4	- 3**	1	\$80.00
Multiple Dependent				\$

Large Fee Code	Entity Fee (\$)	Small Fee Code	Entity Fee (\$)	Fee Description
103	18	203	9	Claims in excess of 20
102	80	202	40	Independent claims in excess of 3
104	270	204	135	Multiple dependent claim
108	80	209	40	**Reissue independent claims over original patent
110	18	210	9	**Reissue claims in excess of 20 and over original patent

**Subtotal (2)** (\$)**862.00**

### 3. ADDITIONAL FEES


Large Fee Code	Entity Fee (\$)	Small Fee Code	Entity Fee (\$)	Fee Description
105	130	205	65	Surcharge - late provisional filing fee or cover sheet
127	50	227	25	Surcharge - late provisional filing fee or cover sheet
139	130	139	130	Non-English specification
147	2,520	147	2,520	For filing a request for <i>ex parte</i> reexamination
112	920	112	920	Requesting publication of SIR prior to Examiner action
113	1,840	113	1,840	Requesting publication of SIR after Examiner action
115	110	215	55	Extension for reply within first month
116	390	216	195	Extension for reply within second month
117	890	217	445	Extension for reply within third month
118	1,390	218	695	Extension for reply within fourth month
128	1,890	228	945	Extension for reply within fifth month
119	310	219	155	Notice of Appeal
120	310	220	155	Filing a brief in support of an appeal
121	270	221	135	Request for oral hearing
138	1,510	138	1,510	Petition to institute a public use proceeding
140	110	240	55	Petition to revive -unavoidable
141	1,240	241	620	Petition to revive - unintentional
142	1,240	242	620	Utility issue fee (or reissue)
143	440	243	220	Design issue fee
144	600	244	300	Plant issue fee
122	130	122	130	Petitions to the Commissioner
123	50	123	50	Petitions related to provisional applications
126	240	126	240	Submission of Information Disclosure Statement
581	40	481	40	Recording each patent assignment per property (times number of properties)
146	710	246	355	Filing a submission after final rejection (37 CFR 1.129(a))
149	710	249	355	For each additional invention to be examined (37 CFR 1.129(b))
179	710	279	355	Request for Continued Examination (RCE)
169	190	169	900	Request for expedited examination of a design application
Other fee (specify):				
Other fee (specify):				
*Reduced by Basic Filing Fee Paid				
<b>Subtotal (3)</b>				

Fee Paid

\$

### Submitted By

Name (Print/Type) **Janet M. Martineau**

Signature: 

Registration No.: **46,903**

Telephone **301-315-2723**

Date **August 27, 2001**

Complete (if applicable)

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: LaFleur et al.

Application Number: to be assigned

Group Art Unit: to be assigned

Filed: herewith

Examiner: to be assigned

Title: 36 Human Secreted Proteins

Attny. Docket No. PZ022P1C2



**REQUEST UNDER 37 C.F.R. § 1.821(e)**

Commissioner for Patents  
Washington, D.C. 20231


Sir :

The above-identified patent application is a continuation of application Serial No. 09/739,907 filed December 20, 2000, which is a continuation of application Serial No. 09/348,457, filed July 7, 1999. The sequence listing of the instant application is identical to the sequence content of the computer readable sequence listing filed in connection with application Serial No. 09/348,457, on July 7, 1999.

In accordance with 37 C.F.R. § 1.821(e), please use the computer readable form filed in connection with application Serial No. 09/348,457 as the computer readable form for the instant application. It is understood that the Patent and Trademark Office will make the necessary change in application number and filing date for the computer readable form that will be used for the instant application. A paper copy of the Sequence Listing is included in the specification of the instant application filed herewith. Applicants hereby certify that the paper copy of the Sequence Listing filed herewith and the computer readable sequence listing filed on July 7, 1999 in connection with application Serial No. 09/348,457 are the same and do not include new matter.

Respectfully submitted

Date: AUGUST 27, 2001

  
Janet M. Martineau (Reg. No. 46,309)  
Attorney for Applicants

Human Genome Sciences, Inc.  
9410 Key West Avenue  
Rockville, MD 20850  
(301) 315-2723 (telephone)

JMM/SA/ur